NCT07776678 Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
| NCT ID | NCT07776678 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Foundation for the National Institutes of Health |
| Condition | Obesity & Overweight |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-06-29 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-06-29 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate body composition across a variety of medical, professional, and commercial devices, including: bioelectrical impedance analysis (BIA) devices, 3-dimensional optical imaging (3DO), manual anthropometry measurements, dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and blood tests. The secondary study purpose is to compare body composition measurements from BIA devices, 3DO, and manual anthropometry measurements within a 1-week period for a subset of the study population. The study plans to enroll 300 healthy (having no life-threatening conditions or diseases; male and female) participants, 18 years of age or older.
Eligibility Criteria
Inclusion Criteria: * Being willing to provide written informed consent prior to participation Being willing to complete the study visits and comply with the study procedures * Being willing to travel to the various study locations for On-site, DXA, MRI, and Phlebotomy visits * Being willing to change into appropriate form-fitting clothing for 3DO assessments and/or appropriate gowns for DXA and MRI imaging * Must have a BMI within the range of 18.5 - 45 kg/m2 * Being willing to refrain from all food, drink, and substances for 8 hours prior to the On-site visit(s) and phlebotomy visit * Being willing to refrain from all food, drink, and substances for 4 hours prior to the DXA and MRI scan visits * Being willing to refrain from any exercise or vigorous physical activity for 24 hours prior to all visits * Stable weight (no more than 5 kg change) for 3 months prior to screening * If recruited in the Phoenix, AZ area, participants must be willing to drive yourself to the Phoenix Office location for the On-site Visits 1 and 2 (if applicable) located at the Exponent Phoenix Office. Exclusion Criteria: * Being pregnant or attempting to become pregnant * Having medical implants, such as a pacemaker or metal joint replacements, or other metal implants contraindicated for MRI * Cosmetic implants, such as breast implants * Having a height greater than DXA scanning limit (77 inches) * Having a body weight greater than indicated for the equipment (400 lbs) * Prior amputation or major body-altering surgery that could invalidate body composition estimates * Having claustrophobia or a history of claustrophobia * Known HIV infection * Known Lipodystrophy * Known hydration abnormality (e.g., significant edema, end-stage renal disease, end-stage liver disease) * Severe illness or life-threatening conditions such as end-stage kidney, liver, lung disease, NYHA III-IV heart failure, or active malignancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07776678 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07776678 currently recruiting?
Yes, NCT07776678 is actively recruiting participants. Contact the research team at bodycompstudy@exponent.com for enrollment information.
Where is the NCT07776678 trial being conducted?
This trial is being conducted at Phoenix, United States, Menlo Park, United States, Boston, United States.
Who is sponsoring the NCT07776678 clinical trial?
NCT07776678 is sponsored by Foundation for the National Institutes of Health. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.